[1]
Zhao, B.; Yuan, C.; Li, R.; Qu, D.; Huang, M.; Ngo, J.C. Crystal structures of matriptase in complex with its inhibitor hepatocyte growth factor activator inhibitor-1. J. Biol. Chem., 2013, 288(16), 11155-11164.
[2]
Uhland, K. Matriptase and its putative role in cancer. Cell. Mol. Life Sci., 2006, 63(24), 2968-2978.
[3]
Welman, A.; Sproul, D.; Mullen, P.; Muir, M.; Kinnaird, A.R.; Harrison, D.J.; Faratian, D.; Brunton, V.G.; Frame, M.C. Diversity of matriptase expression level and function in breast cancer. PLoS One, 2012, 7(4), e34182.
[4]
Bergum, C.; Zoratti, G.; Boerner, J.; List, K. Strong expression association between matriptase and its substrate prostasin in breast cancer. J. Cell. Physiol., 2012, 227(4), 1604-1609.
[5]
Oberst, M.D.; Johnson, M.D.; Dickson, R.B.; Lin, C.Y.; Singh, B.; Stewart, M.; Williams, A.; Al-Nafussi, A.; Smyth, J.F.; Gabra, H.; Sellar, G.C. Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: Correlation with clinical outcome and tumor clinicopathological parameters expression of the serine protease matriptase and its inhibitor HAI- 1 in epithel. Clin. Cancer Res., 2002, 8(4), 1101-1107.
[6]
Godiksen, S.; Soendergaard, C.; Friis, S.; Jensen, J.K.; Bornholdt, J.; Sales, K.U.; Huang, M.; Bugge, T.H.; Vogel, L.K. Detection of active matriptase using a biotinylated chloromethyl ketone peptide. PLoS One, 2013, 8(10), e77146.
[7]
Friedrich, R.; Fuentes-Prior, P.; Ong, E.; Coombs, G.; Hunter, M.; Oehler, R.; Pierson, D.; Gonzalez, R.; Huber, R.; Bode, W.; Madison, E.L. Catalytic domain structures of MT-SP1/matriptase, a matrix-degrading transmembrane serine proteinase. J. Biol. Chem., 2002, 277(3), 2160-2168.
[8]
Quimbar, P.; Malik, U.; Sommerhoff, C.P.; Kaas, Q.; Chan, L.Y.; Huang, Y.H.; Grundhuber, M.; Dunse, K.; Craik, D.J.; Anderson, M.A.; Daly, N.L. High-affinity cyclic peptide matriptase inhibitors. J. Biol. Chem., 2013, 288(19), 13885-13896.
[9]
Maya, H.; Eggert, R.; Eva, M.; Andreas, H.; Michael, G.; Gerhard, K.; Torsten, S. New 3-amidinophenylalanine derived inhibitors of matriptase. MedChemComm, 2012, 3, 807-813.
[10]
Munteanu, C.R.; Fernández-Blanco, E.; Seoane, J.A.; Izquierdo-Novo, P.; Rodríguez-Fernández, J.A.; Prieto-González, J.M.; Rabuñal, J.R.; Pazos, A. Drug discovery and design for complex diseases through QSAR computational methods. Curr. Pharm. Des., 2010, 16(24), 2640-2655.
[11]
Kubinyi, H. QSAR and 3D QSAR in drug design. Part 1: Methodology. Drug Discov. Today, 1997, 2(11), 457-467.
[12]
Pecka, J.; Ponec, R. Simple analytical method for evaluation of statistical importance of correlations in QSAR studies. J. Math. Chem., 2000, 27(1-2), 13-22.
[13]
Carb-Dorca, R.; Besal, E. Extending molecular similarity to energy surfaces: Boltzmann similarity measures and indices. J. Math. Chem., 1996, 20(2), 247-261.
[14]
Quimbar, P.; Malik, U.; Sommerhoff, C.P.; Kaas, Q.; Chan, L.Y.; Huang, Y.H.; Grundhuber, M.; Dunse, K.; Craik, D.J.; Anderson, M.A.; Daly, N.L. High-affinity cyclic peptide matriptase inhibitors. J. Biol. Chem., 2013, 288(19), 13885-13896.
[15]
Bkhaitan, M.M.; Mirza, A.Z.; Shamshad, H.; Ali, H.I. Identification of potent virtual leads and ADME prediction of isoxazolidine podophyllotoxin derivatives as topoisomerase II and tubulin inhibitors. J. Mol. Graph. Model., 2017, 73, 74-93.
[16]
RCSB PDB, University of New Jersey, Department of Chemistry and Chemical Biology 610 Taylor Road, (n.d.)..
[17]
Bkhaitan, M.M.; Mirza, A.Z.; Abdalla, A.N.; Shamshad, H.; Ul-Haq, Z.; Alarjah, M.; Piperno, A. Reprofiling of full-length phosphonated carbocyclic 2′-oxa-3′-aza-nucleosides toward antiproliferative agents: Synthesis, antiproliferative activity, and molecular docking study. Chem. Biol. Drug Des., 2017, 90(5), 679-689.
48
2